Dr. Reddy’s and Alvotech Collaborate on Keytruda Biosimilar

Dr Reddy’s Laboratories ( (RDY) ) has issued an announcement.

On June 5, 2025, Dr. Reddy’s Laboratories announced a collaboration with Alvotech to co-develop a biosimilar candidate to Keytruda® (pembrolizumab), a leading cancer treatment. This partnership aims to leverage both companies’ expertise in biosimilars to accelerate development and expand global market reach. The collaboration is expected to enhance Dr. Reddy’s capabilities in oncology, a key focus area, and provide cost-effective treatment options worldwide.

The most recent analyst rating on (RDY) stock is a Buy with a $17.00 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page.

Spark’s Take on RDY Stock

According to Spark, TipRanks’ AI Analyst, RDY is a Outperform.

Dr Reddy’s Laboratories receives a solid overall score due to its strong financial performance, especially in revenue growth and balance sheet stability. Technical indicators show positive momentum, although the stock is below its long-term average. Valuation is reasonable, but dividend yield is low. The recent earnings call was positive, highlighting growth and strategic advancements despite some market challenges.

To see Spark’s full report on RDY stock, click here.

More about Dr Reddy’s Laboratories

Dr. Reddy’s Laboratories is a multinational pharmaceutical company based in Hyderabad, India. The company specializes in the development, manufacture, and marketing of a wide range of pharmaceutical products, including biosimilars, which are biologic medical products highly similar to already approved reference products. Dr. Reddy’s focuses on providing affordable and innovative medicines to patients globally, with a strong emphasis on oncology and other critical therapeutic areas.

Average Trading Volume: 2,055,866

Technical Sentiment Signal: Strong Buy

Current Market Cap: $12.13B

For a thorough assessment of RDY stock, go to TipRanks’ Stock Analysis page.